FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220783891> ?p ?o ?g. }

• W4220783891 abstract "This study aimed to explore the shared mechanism and candidate drugs of multiple sclerosis (MS) and Sjögren's syndrome (SS).MS- and SS-related susceptibility genes and differentially expressed genes (DEGs) were identified by bioinformatics analysis based on genome-wide association studies (GWAS) and transcriptome data from GWAS catalog and Gene Expression Omnibus (GEO) database. Pathway enrichment, Gene Ontology (GO) analysis, and protein-protein interaction analysis for susceptibility genes and DEGs were performed. The drugs targeting common pathways/genes were obtained through Comparative Toxicogenomics Database (CTD), DrugBank database, and Drug-Gene Interaction (DGI) Database. The target genes of approved/investigational drugs for MS and SS were obtained through DrugBank and compared with the common susceptibility genes.Based on GWAS data, we found 14 hub common susceptibility genes (HLA-DRB1, HLA-DRA, STAT3, JAK1, HLA-B, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRB5, HLA-DPA1, HLA-DPB1, TYK2, IL2RA, and MAPK1), with 8 drugs targeting two or more than two genes, and 28 common susceptibility pathways, with 15 drugs targeting three or more than three pathways. Based on transcriptome data, we found 3 hub common DEGs (STAT1, GATA3, PIK3CA) with 3 drugs and 10 common risk pathways with 435 drugs. JAK-STAT signaling pathway was included in common susceptibility pathways and common risk pathways at the same time. There were 133 overlaps including JAK-STAT inhibitors between agents from GWAS and transcriptome data. Besides, we found that IL2RA and HLA-DRB1, identified as hub common susceptibility genes, were the targets of daclizumab and glatiramer that were used for MS, indicating that daclizumab and glatiramer may be therapeutic for SS.We observed the shared mechanism of MS and SS, in which JAK-STAT signaling pathway played a vital role, which may be the genetic and molecular bases of comorbidity of MS with SS. Moreover, JAK-STAT inhibitors were potential therapies for MS and SS, especially for their comorbidity." @default.
• W4220783891 created "2022-04-03" @default.
• W4220783891 creator A5006822602 @default.
• W4220783891 creator A5006912868 @default.
• W4220783891 creator A5011740583 @default.
• W4220783891 creator A5015739988 @default.
• W4220783891 creator A5025996303 @default.
• W4220783891 creator A5066501569 @default.
• W4220783891 creator A5070812231 @default.
• W4220783891 creator A5073088792 @default.
• W4220783891 creator A5085224831 @default.
• W4220783891 date "2022-03-09" @default.
• W4220783891 modified "2023-10-06" @default.
• W4220783891 title "The Shared Mechanism and Candidate Drugs of Multiple Sclerosis and Sjögren’s Syndrome Analyzed by Bioinformatics Based on GWAS and Transcriptome Data" @default.
• W4220783891 cites W1973237459 @default.
• W4220783891 cites W1991500494 @default.
• W4220783891 cites W2057102103 @default.
• W4220783891 cites W2086465880 @default.
• W4220783891 cites W2102938736 @default.
• W4220783891 cites W2118258530 @default.
• W4220783891 cites W2133465414 @default.
• W4220783891 cites W2145521029 @default.
• W4220783891 cites W2146512944 @default.
• W4220783891 cites W2146962585 @default.
• W4220783891 cites W2158217645 @default.
• W4220783891 cites W2159675211 @default.
• W4220783891 cites W2162981836 @default.
• W4220783891 cites W2263478463 @default.
• W4220783891 cites W2329190288 @default.
• W4220783891 cites W2528968729 @default.
• W4220783891 cites W2560140067 @default.
• W4220783891 cites W2592914480 @default.
• W4220783891 cites W2615759607 @default.
• W4220783891 cites W2767891136 @default.
• W4220783891 cites W2784734333 @default.
• W4220783891 cites W2793352806 @default.
• W4220783891 cites W2805421097 @default.
• W4220783891 cites W2808789152 @default.
• W4220783891 cites W2883148575 @default.
• W4220783891 cites W2900135454 @default.
• W4220783891 cites W2900569176 @default.
• W4220783891 cites W2901303766 @default.
• W4220783891 cites W2919906631 @default.
• W4220783891 cites W2939980218 @default.
• W4220783891 cites W2973019461 @default.
• W4220783891 cites W3006836229 @default.
• W4220783891 cites W3008368974 @default.
• W4220783891 cites W3021843660 @default.
• W4220783891 cites W3087620170 @default.
• W4220783891 cites W3092264232 @default.
• W4220783891 cites W3093194543 @default.
• W4220783891 cites W3102585837 @default.
• W4220783891 cites W3107626709 @default.
• W4220783891 cites W3109341372 @default.
• W4220783891 cites W3118775651 @default.
• W4220783891 cites W3121322227 @default.
• W4220783891 cites W3151917828 @default.
• W4220783891 cites W3154233248 @default.
• W4220783891 cites W3156903078 @default.
• W4220783891 cites W3163977729 @default.
• W4220783891 cites W3175752499 @default.
• W4220783891 cites W3176937101 @default.
• W4220783891 cites W3177367930 @default.
• W4220783891 cites W3193861087 @default.
• W4220783891 cites W3204327959 @default.
• W4220783891 cites W3208038855 @default.
• W4220783891 cites W4211090999 @default.
• W4220783891 cites W4253381763 @default.
• W4220783891 cites W4287665063 @default.
• W4220783891 doi "https://doi.org/10.3389/fimmu.2022.857014" @default.
• W4220783891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35356004" @default.
• W4220783891 hasPublicationYear "2022" @default.
• W4220783891 type Work @default.
• W4220783891 citedByCount "5" @default.
• W4220783891 countsByYear W42207838912022 @default.
• W4220783891 countsByYear W42207838912023 @default.
• W4220783891 crossrefType "journal-article" @default.
• W4220783891 hasAuthorship W4220783891A5006822602 @default.
• W4220783891 hasAuthorship W4220783891A5006912868 @default.
• W4220783891 hasAuthorship W4220783891A5011740583 @default.
• W4220783891 hasAuthorship W4220783891A5015739988 @default.
• W4220783891 hasAuthorship W4220783891A5025996303 @default.
• W4220783891 hasAuthorship W4220783891A5066501569 @default.
• W4220783891 hasAuthorship W4220783891A5070812231 @default.
• W4220783891 hasAuthorship W4220783891A5073088792 @default.
• W4220783891 hasAuthorship W4220783891A5085224831 @default.
• W4220783891 hasBestOaLocation W42207838911 @default.
• W4220783891 hasConcept C104317684 @default.
• W4220783891 hasConcept C106208931 @default.
• W4220783891 hasConcept C135763542 @default.
• W4220783891 hasConcept C150194340 @default.
• W4220783891 hasConcept C153209595 @default.
• W4220783891 hasConcept C155261790 @default.
• W4220783891 hasConcept C162317418 @default.
• W4220783891 hasConcept C2780035454 @default.
• W4220783891 hasConcept C54355233 @default.
• W4220783891 hasConcept C60644358 @default.
• W4220783891 hasConcept C69991583 @default.
• W4220783891 hasConcept C70721500 @default.
• W4220783891 hasConcept C86803240 @default.

• next